

[Redacted]

$t_{1/2}$ was 30 h at the 4 mg/kg dose. The majority of the exposure was accounted for, during the 120 h period post start of dosing, as the extrapolated percentages of AUC from time t to infinity were generally < 5 %. The rapid plasma clearance and high $t_{1/2}$ were generally consistent with the observed pharmacokinetic profile.

levelling off
and AUC_{0-t} values to c

[Redacted]

F901318 demonstrated predictable and linear single dose pharmacokinetics over the dose range of 0.25 mg/kg-4 mg/kg. The pharmacokinetic profile displayed by F901318 and the exposures achieved in this single dose intravenous study are in line with the preclinical PK scaling predictions and on target for PK/PD predicted efficacy exposures on repeat dosing. These PK results combined with an excellent safety profile warrant progression of F901318 into further clinical studies.